drugset / Trial / NCT01784523
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
Phase 3
Terminated
11 enrolled
Hospital for Special Surgery, New York
AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking · collabThe New York Community Trust · collab
RandomizedSingle-groupOpen-labelPrevention
Summary
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-09-30
- Completion
- 2015-09-30
Publications
- Background Erkan D, Lockshin MD; APS ACTION members. APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012 Jun;21(7):695-8. doi: 10.1177/0961203312437810.
- Background Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011 Feb;20(2):219-24. doi: 10.1177/0961203310395053.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 200 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 400 mg | — |